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Background: Low serum levels of alkaline phosphatase (ALP) are a hallmark of 
hypophosphatasia. However, the clinical significance and the underlying genetics of low ALP 
in unselected populations are unclear.  
Methods: In order to clarify this issue, we performed a clinical, biochemical and 
genetic study of 42 individuals (age range 20-77 yr) with unexplained low ALP levels.  
Results: Nine had mild hyperphosphatemia and three had mild hypercalcemia. ALP 
levels were inversely correlated with serum calcium (r=-0.38, p=0.012), pyridoxal phosphate 
(PLP; r= -0.51, p=0.001) and urine phosphoetenolamine (PEA; r= -0.49, p=0.001). Although 
many subjects experienced minor complaints, such as mild musculoskeletal pain, none had 
major health problems. Mutations in ALPL were found in 21 subjects (50%), including six 
novel mutations. All but one, were heterozygous mutations. Missense mutations were the 
most common (present in 18 subjects; 86%) and the majority were predicted to have a 
damaging effect on protein activity. The presence of a mutated allele was associated with 
tooth loss (48% versus 12%; p=0.04), slightly lower levels of serum ALP (p=0.002), higher 
levels of PLP (p<0.0001) and PEA (p<0.0001), as well as mildly increased serum phosphate 
(p=0.03). Ten individuals (24%) had PLP levels above the reference range; all carried a 
mutated allele.  
Conclusion: One-half of adult individuals with unexplained low serum ALP carried an 
ALPL mutation. Although the associated clinical manifestations are usually mild, in 
approximately 50% of the cases, enzyme activity is low enough to cause substrate 
accumulation and may predispose to defects in calcified tissues.   
 
KEYWORDS: alkaline phosphatase; hypophosphatasia; mutation analysis; pyridoxal 
phosphate; phosphoethanolamine; ALPL. 
 3 
INTRODUCTION 
The clinical significance of low serum levels of alkaline phosphatase (ALP) is unclear 
and consequently clinicians may not pay attention to them. In fact, low ALP may be an 
irrelevant finding or accompany various systemic disorders (1;2).  However, in some cases 
low ALP levels are the consequence of an underlying genetic disorder, hypophosphatasia, 
which influences tissue homeostasis, as well as drug responses. 
Hypophosphatasia is a rare skeletal disorder due to a genetic defect in ALPL, the gene 
encoding the tissue-nonspecific (liver/bone/kidney) isoenzyme of ALP (3-5) or TNSALP. 
TNSALP is a homodimeric enzyme, with each monomer consisting of 524 amino acids. It 
connects to the cell membrane and functions as an ectophosphatase, hydrolyzing inorganic 
pyrophosphate (PPi), an inhibitor of mineralization, and other phosphate esters (6).  Apart 
from TNSALP, the ALP family comprises of three tissue specific ALPs: intestinal, encoded 
by ALPI; placental, encoded by ALPP;  and placental-like 2 or germ cell, encoded by 
ALPPL2 (7). ALPL consists of 12 exons, of which the first and part of the second are 
noncoding.  Several forms of hypophosphatasia have been described, mainly in children (6;8), 
with considerable variations in the disease spectrum, even within the same family (9).  
Low serum ALP activity is frequently the first finding leading to a suspicion of 
hypophosphatasia. The diagnosis may be confirmed by genetic testing or by measuring other 
phosphorylated substrates, such as pyridoxal-5'-phosphate (PLP) or phosphoethanolamine 
(PEA) (8).  Hypophosphatasia in adults may either represent late manifestations of cases 
discovered in childhood, or adult onset forms (10-13). Cases with less severe manifestations 
may pass unrecognized. However, they may have important consequences, including an 
increased risk of adverse effects after taking medication frequently used for treating 
osteoporosis, i.e. bisphosphonates (14).  On the other hand, the significance of lone low serum 
levels of ALP is unclear. Therefore, the aim of this study was to get a better understanding of 
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the spectrum of low ALP levels in adults, by the active search of cases and the clinical, 
biochemical and genetic characterization of subjects with reduced serum ALP activity.    
 
MATERIALS AND METHODS 
Subjects 
We reviewed serum ALP measurements in individuals aged 18 years and older during 
a 30-month period, in the Clinical Biochemistry laboratory, Hospital University Marqués 
Valdecilla, a tertiary facility serving a population of about 350,000 in Northern Spain. The 
clinical records of individuals with consistently low levels of ALP (see details in Results) 
were reviewed to exclude secondary causes of low ALP levels (2). Thus, patients with renal 
failure, malnutrition or antiresorptive drugs, were excluded. Then, individuals with 
consistently low levels of ALP of unknown cause were contacted by telephone and offered to 
participate in the study. It included a clinical interview with a standard protocol, a physical 
examination and obtaining blood and urine samples for biochemical and genetic analyses. The 
study was approved by the Institutional Review Board and all participants gave informed 
written consent. 
 
Biochemical and genetic analyses 
ALP was measured by a colorimetric method in an Advia 2400 analyzer (Siemens 
Healthcare, Munich, Germany). The reference range in adults is 40-129 U/l.  Serum calcium 
and phosphorus were also measured in an Advia 2400 analyzer (Arsenazo III and 
Phosphomolybdate methods, respectively). Following manufacturer’s instructions. The 
reference ranges were 8.1-10.4 mg/dl and 2.3-4.0 mg/dl, respectively. The bone isoenzyme of 
alkaline phosphatase (BAP) was measured by enzymoimmunoassay (Microvue BAP EIA kit, 
Quidel Corporation, San Diego, CA, USA); with a reference range of 12-43 U/l. PEA and 
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PLP were measured at Reference laboratory (Barcelona, Spain). Urinary PEA was measured 
by HPLC (derivatization with o-phthalaldehyde and reverse phase high performamnce liquid 
chromatography with fluorescence detection); normal levels are below 70 µmol/g creatinine. 
PLP was determined by an enzymatic assay (VB6 enzymatic PoBühlmann, Bühlmann 
Laboratories AG, Switzerland); the reference range was 23-173 nmol/l. 
The screening of the coding sequences and intron/exon boundaries of ALPL 
(NM_000478.4) was performed by direct sequencing.  Primers were designed with the help of 
Primer 3 v0.4.0 software (http://bioinfo.ut.ee/primer3-0.4.0/) and SNPCheck V3 
(https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm) (Table 1). PCR products were 
sequenced using the BrightDye Terminator cycle kit (Nimagen, Nijmegen, The Netherlands) 
and run on an ABI3730XL Sequencer (Applied Biosystems, Foster City, CA).  Conservation, 
in silico pathogenicity prediction and control population frequency analysis (ExoAC, Exome 
aggregation consortium) of the identified ALPL variants was carried out using Alamut V2.6-1 
software (Interactive Biosoftware, Rouen, France) and MutPred (http://mutpred.mutdb.org/) 
and the evolutionary criteria proposed by Silvent et al (7).We also consulted the ALPL 
mutation database (http://www.sesep.uvsq.fr/03_hypo_mutations.php) to check if any 
detected variant had been previously described, supporting its pathogenicity. We adopted the 
recommendations and guidelines of the American College of Medical Genetics and Genomics 
(15). 
 
Statistical analysis  
Comparisons between groups were analyzed by Mann-Whitney U tests or Chi2 tests, 
as indicated. The correlation between biochemical parameters was estimated as the 
Spearman’s correlation coefficient. All tests were 2-tailed and p-values less than 0.05 were 




After searching the laboratory database (n= ~500,000 ALP analyses), we identified 
12,546 serum ALP determinations in 8,758 patients below the lower limit of the reference 
range (40 U/l). A more stringent 26 U/l threshold was chosen hereafter to increase specificity 
and avoid including individuals with occasional values below the standard normal range, 
likely to lack biological relevance. In 466 blood tests, performed in 181 patients, the enzyme 
level was <26 U/l. Among them, 130 individuals had persistently low levels (defined for the 
purpose of this study as at least one test result <26 U/l and none >40 U/l prior to the current 
study). After reviewing the clinical records, unexplained persistently low levels were found in 
50 individuals. Of these, 42 unrelated subjects (10 men, 32 women) with an age range of 20-
77 years (mean 50, median 49) were willing to participate in the study. A physician 
interviewed them and blood and urine samples were obtained for analysis. 
Many subjects were asymptomatic or had mild ailments. A total of 24 complained of 
mild skeletal or muscular pain; 12 had suffered fractures (most were related to trauma and 
could not be necessarily considered due to bone fragility); two had a history of periarthritis 
and/or tendinopathy; nine had a diagnosis of osteoarthritis; nine, hypertension; one, coronary 
heart disease; and 13 had lost one or more teeth in the absence of trauma before 40 years of 
age. 
Total ALP levels were positively correlated with BAP, and negatively with serum 
calcium (r=-0.38, p=0.01), serum PLP (r=-0.51, p=0.001), and urine PEA (r=-0.49, p=0.001) 
(table 2, Fig. 1). Serum PLP correlated with serum phosphorus (r=0.49, p=0.001) and urinary 
PEA (r=0.58, p<0.001), and negatively with BAP (r=-0.54, p<0.001). Urinary PEA levels 
were within the reference range in all but one subject. Nine patients had mild 
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hyperphosphatemia, whereas three had serum calcium levels slightly above the upper 
reference limit (Fig. 2). 
ALPL mutations were found in 21/42 subjects (20 heterozygotes and 1 homozygote), 
including nine previously published (16-23) and six unreported mutations (Table 3). Most 
mutations were observed in single patients. However, the substitution p.(Thr166Ile) was 
present in three patients, whereas two other changes, p.(Ser181Leu) and p.(Thr148Ile), were 
each present in two subjects. Eighteen patients (86%) had a missense mutation; two had 
frameshift mutations; and one had a splice site mutation. The majority of the mutations were 
located in exons 5 and 6 (12 amino acids mutated in 17 patients), all of which were predicted 
to have a damaging effect on protein activity using bioinformatics algorithms and were absent 
or at extremely low frequency in control populations (Table 3).   
The presence of a mutated allele was associated with early tooth loss (48% vs. 12%; 
p=0.04), slightly lower ALP (30±6 vs. 25±6 u/l; p=0.002), higher levels of enzyme substrates, 
such as serum PLP (p<0.0001) and urine PEA (p<0.0001), and serum phosphate (p=0.03) 
(Fig.2). Ten patients had PLP levels above the normal range, all of whom carried a gene 
mutation.  The patient with the c.352C>A [p.Leu118Met);(Leu118Met)] homozygous 
mutation did not show obvious clinical differences to those with heterozygous mutations (she 
only had mild bone pain and low alkaline phosphatase levels). The variant was predicted to be 
pathogenic in 2/4 in silico analysis and absent from all control population databases. Thus, 
this variant is a variant of unknown significance. 
 
DISCUSSION 
Hypophosphatasia is a rare disorder with a prevalence of the severe form between 0.3-
1/100,000 (8). Less severe forms, as those observed in adults, may be considerably more 
frequent, up to 1/6,000 in European populations (24). In a recent study, persistent 
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hypophosphatasemia was found in 1/1,544 adult patients seen at a multispeciality health clinic 
(25). A low ALP level is frequently the first clue pointing to hypophosphatasia. However, it 
may also have secondary non-genetic causes, such as therapy with anti-resorptive drugs, renal 
failure-associated adynamic bone disease, celiac disease, hypothyroidism, multiple myeloma, 
etc. (1;2;14;25). Also, serum ALP may transiently decrease in severe acute diseases (2), 
probably reflecting the inhibition of osteoblast activity accompanying the stress response (26). 
In the present series, we found that 50% of adults with repeatedly low ALP levels had 
a mutation in ALPL. All mutations were predicted to impair the enzyme activity. In fact, 
haploinsufficiency was enough to reduce serum ALP activity, and in about one-half of the 
cases with mutations there was biochemical evidence of accumulation of phosphorylated 
substrates, such as PLP. About 285 loss of function ALPL mutations have been described to 
date; most of them missense mutations (3), as it was also observed in the present study. A 
French reference laboratory suggested that the mutation c.571G>A (p.Glu191Lys) may be 
particularly frequent in European cases with mild forms (3), but this mutation was absent in 
our cohort. However, we detected eight mutations that had not been previously reported. In 
our series, mutations tended to accumulate in exons 5 and 6. This could be due to the fact 
those exons encode highly conserved sequences (96% and 98% across species, respectively 
(7)), involved in several functionally important domains, including the homodimeric interface 
and active sites. Hence, even heterozygous mutations could have an effect on enzyme activity. 
No mutation was identified in 21 individuals with low ALP levels. These might either 
represent the lower extreme of the normal distribution, or be carriers of a mutation in an 
intron or regulatory region of ALPL. Whatever the explanation, all individuals with a normal 
genetic study had normal levels of PLP and PEA. Therefore, the remaining enzyme activity 
appeared to be enough to avoid the accumulation of ALP substrates. 
 9 
In practice, the diagnosis of hypophosphatasia is usually established by the 
combination of suggestive clinical manifestations, low ALP, and high levels of serum PLP or 
urinary PEA (8). However, PLP seems to have much higher sensitivity than PEA (6;8). In 
fact, only one individual in this series had PEA levels above the reference range, yet several 
had markedly increased PLP. There was no close association between serum PLP and ALP, 
but all individuals with high PLP levels had a mutated allele. Therefore, in the absence of 
genetic data, PLP seems to be a good diagnostic marker.   
Perinatal and infantile hypophosphatasia are autosomal recessive diseases. The milder 
forms may be inherited in a recessive or dominant manner (3;23;27). Heterozygotes who are 
carriers of a recessive mutation may be asymptomatic or have mild symptoms. However, the 
spectrum of this disorder is broad-ranging, even within members of the same family sharing 
the same mutation (9). Skeletal problems described in adult patients with hypophosphatasia 
include abnormalities of the bone, joint and soft-tissues, such as osteomalacia, low-bone mass 
and microarchitectural abnormalities, chondrocalcinosis, osteoarthritis, periarthritis, 
premature loss of teeth, myopathy, enthesopathy, etc. (11-13).  
A few patients in our analysis exhibited some of these abnormalities; tooth loss being 
the most common, but many had no obvious skeletal problems. It is unclear to what extent 
some mild symptoms, such as aches and pains were related to low ALP activity or just 
incidental findings. On the other hand, the majority of our patients were relatively young 
(7/42 were >65 years), and it is unclear whether they will suffer hypophosphatasia-associated 
skeletal problems with aging. Also, since we did not perform routine imaging studies, some 
skeletal abnormalities may have gone unnoticed. In a recent report of 22 patients with 
symptomatic hypophosphatasia diagnosed in adulthood, the median age at symptom onset 
was 44 yr. Muscular pain and fractures were the most common manifestations. Interestingly, 
only 9% of patients had a positive family history (13).  
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Overall, our results suggest that most adult individuals with low ALP levels, even 
those with confirmed gene mutations and deficient ALP activity, are asymptomatic or have 
only mild manifestations. Yet, it is important to identify this disorder. Even in the absence of 
specific clinical manifestations, individuals with ALP deficiency may be at risk of developing 
adverse effects when they are prescribed antiresorptive drugs, such as bisphosphonates. The 
occurrence of atypical femoral fractures, although rare, is an adverse effect of these drugs that 
has been increasingly recognized in recent years (28-30). Bisphosphonates are analogues of 
PPi that suppress bone turnover but also might deactivate ALP (14). The pathogenesis of 
atypical fractures is unclear, but it may be related to the inhibition of bone turnover and the 
accumulation of non-healing microfractures. Although most patients with atypical fractures 
do not have evidence of ALPL mutations  (31), individuals with low ALP activity may be at 
increased risk. In fact, patients with hypophosphatasia and bisphosphonate-related atypical 
fractures have been reported (14). Likewise, prescribing bisphosphonates to patients with low 
ALP activity and renal insufficiency may be particularly risky (32). Thus, at minimum a 
determination of serum PLP should be obtained in individuals with persistently low ALP 
levels, even in the absence of specific complains. If PLP is increased, a genetic analysis may 
be considered. 
In conclusion, 50% of adult individuals with persistent low levels of serum ALP had a 
mutation in ALPL. Although clinical manifestations are usually mild, in about 50% of cases 
the enzymatic activity is low enough to cause the accumulation of phosphorylated substrates. 
These individuals might be classified as having an occult, oligosymptomatic form of 
hypophosphatasia. This diagnosis should be carefully considered in any individual with 
unexplained low levels of ALP, especially if treatment with antiresorptive agents is to be 




 Most patients with unexplained low levels of alkaline phosphatase are asymptomatic or 
have minor musculoskeletal complains or biochemical abnormalities of mineral 
metabolism. 
 About one half of them carry a mutation in the coding region of the ALPL gene, usually in 
heterozygous state. Of these, about one half have evidence of reduced enzyme activity 
enough to cause substrate accumulation.  
 In the absence of genetic testing, serum pyridoxal phosphate (PLP) has higher sensitivity 
for diagnosis than other parameters, such as urinary phosphoethanolamine. 
 Patients with reduced alkaline phosphatase might be at increased risk of complications if 
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Figure 1. Correlations between alkaline phosphatase (ALP) activity, bone alkaline 
phosphatase (BAP) and the substrate levels (pridoxal-5'-phosphate [PLP] and urinary 
phosphoethanolamine [PEA]) in 42 adults with low serum ALP.  
 
Figure 2. Biochemical data of the 42 subjects. Alkaline phosphatase (ALP), calcium (Ca), 
phosphorus (P), bone alkaline phosphatase (BAP), urinary phosphoethanolamine (PEA) and 
pyridoxal-5'-phosphate (PLP) in individuals with ALP activity and either an ALPL mutation 
(black circles, n=21) or no mutation (open circles, n=21). The dotted lines mark the limits of 
the reference ranges. 
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Table 1. Primers sequences and amplicon sizes of the analysed ALPL exons.   
ALPL 
exon 
Forward (5´>3´) Reverse (5´>3´) Amplicon 
size (bp) 
2 TCAGTTAACATCTGACCACTGC CCCTCATCATACCCCATCTG 215 
3 CACCTCCAAGTTCAGGCATT AAACACCCTTCCTCCAGAGC 352 
4 TACAGAGCCATGCCCAGTG CTCTGGCTGCTGTCATGTTC 326 
5 AGTCCCCATGGTGTGAGTGT AAGCCTTTTCTAGCCCCTTC 357 
6 AGGAGGCCTCTGGGACAC GAGCCCATGGAGGAAAGATT 364 
7 AAGTGTCCACACCATCTCCAG GAGCCCATGGAGGAAAGATT 382 
8 GATAGCTGCTGGGGTCAGTC CTAAGTGGGCGTCAGGCTA 247 
9 CCAGCCACCATACTCTACCC ACCCCCAAACCAGTCAGTTC 366 
10 TGGTGCTAGCTCAGAGTGGT TGTCATTGAGTCCCCACCAT 449 
11 AAGCCACCAAGGAGCCTAAT GCTGACACCCTATTCCCAAG 280 
12 CCTGGAAGGGAGATGGAAA TGTGGGAAGTTGGCATCTGT 399 
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Table 2. Spearman´s coefficients and p-values of correlations between several serum 
parameters and urine PEA. 
 
  ALP Calcium Phosphorus BAP PEA 
Calcium r = -0.382     
p = 0.012     
Phosphorus r = -0.089 r = 0.178    
p = 0.573 p = 0.258    
BAP r = 0.519 r = -0.269 r = -0.196   
p < 0.001 p = 0.085 p = 0.213   
PEA r = -0.487 r = 0.406 r = 0.503 r = -0.490  
p = 0.001 p = 0.008 p = 0.001 p = 0.001  
PLP r = -0.513 r = 0.223 r = 0.494 r = -0.538 r = 0.678 
p = 0.001 p = 0.155 p = 0.001 p < 0.001 p < 0.001 
ALP: total alkaline phosphatase 
BAP: bone alkaline phosphatase 










Mutation      
(cDNA)  
Mutation                        
(Amino acid) 
Polyphen2 SIFT MutationTaster MutPred Conservation  Frequency 
(ExoAC) 
Reference 
HPP4 5 c.334G>A p.(Gly112Ser)  Prob 
damaging                       
(1.00) 
Tolerated    
(0.25) 




Yes  - Witters et 
al, 2004  
HPP5 5 c.382G>A p.(Val128Met) Prob 
damaging                    
(0.993) 
Damaging         
(0)




CP  - Mumm et 
al, 2002  
HPP7 12 c.1366G>A p.(Gly456Arg) Prob 
damaging                       
(1.00) 
Damaging           
(0)









6 c.497C>T p.(Thr166Ile) Prob 
damaging                        
(1.00) 
Damaging         
(0)




Yes  - - 
HPP15 5 c.334G>C p.(Glu112Arg) Prob 
damaging                        
(1.00) 
Damaging         
(0.04) 




Yes  - -  
HPP18 
HPP34 
6 c.542C>T p.(Ser181Leu)  Poss 
damaging               
(0.947) 
Damaging        
(0.17) 










al, 2001  
HPP19 
HPP21 
5 c.443C>T p.(Thr148Ile) Prob 
damaging              
(0.994) 
Tolerated        
(0.06) 




Yes  - Spentchian 
et al, 2003  
HPP23 12 c.1417G>A p.(Gly473Ser)  Prob 
damaging                        
(1.00) 
Damaging         
(0.02) 




Yes  - Mornet et 
al, 1998  
HPP24 10 c.1083_1084dup p.(Ser364Argfs*42) - - - - -  -  - 
HPP26 Int5 c.473-2A>G N/A - - - - -  - - 
HPP28 5 c.454C>T p.(Arg152Cys) Benign                   
(0.072)  
Damaging    
(0.03) 
DC                 
(0.992) 
- CP  - Mornet et 
al, 2009  
 19 
HPP29 5 c.407G>A p.(Arg136His)  Prob 
damaging                               
(1.00) 
Tolerated    
(0.12) 









et al, 1999  
HPP33 5 c.358G>A p.(Gly120Arg)  Prob 
damaging                       
(0.999) 
Damaging           
(0)




Yes  - Mornet et 
al, 1998  
HPP35 5 c.352C>A;c.352C>A p.(Leu118Met);(Leu118Met)  DC                              
(1.00) 
Tolerated         
(0.06) 




Yes  - - 
HPP36 9 c.871G>A p.Glu291Lys) DC                        
(1.00) 
Damaging         
(0.38) 




Yes  - Mornet et 
al, 1998  
HPP37 5 c.383_384insG p.(Val130Glyfs*6) - - - - Yes  - - 
HPP40 6 c.512A>G p.(His171(Arg)  DC           
(1.00) 
Damaging          
(0.04) 
DC                
(1.00) 





al, 2001  
 
HPP Nº represents our patient sample internal code, nucleotide nomenclature according to transcript NM_000478.4. Several predictors were applied to 
study the possible pathogenic effects of each mutation. Prob damaging (probably damaging, Poss damaging (Possibly damaging, DC, disease causing; B, 
benign;. Scores indicates the pathogenicity possibility of each mutation. Information about the Polyphen, SIFT, MutationTaster scores can be find on the 
user guide of Alamut V2.6-1  Software (http://www.interactive-biosoftware.com/) and MutPred scores at http://mutpred.mutdb.org/about.html. Species 
conservation according to Silvent et al (7), CP, conservative position (substitution conserving chemical properties). Population frequencys in ExoAC (EA: 


















































Fig. 2  
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